Reuters: Health
AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
Reuters: Health
AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.
Reuters: Health
AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment